Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,306,346
  • Shares Outstanding, K 74,760
  • Annual Sales, $ 772,600 K
  • Annual Income, $ 131,100 K
  • 36-Month Beta 0.51
  • Price/Sales 3.02
  • Price/Cash Flow 15.71
  • Price/Book 2.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.34
  • Number of Estimates 3
  • High Estimate 0.39
  • Low Estimate 0.31
  • Prior Year 0.31
  • Growth Rate Est. (year over year) +9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.63 +0.10%
on 11/12/18
46.76 -36.57%
on 10/31/18
-13.84 (-31.82%)
since 10/12/18
3-Month
29.63 +0.10%
on 11/12/18
50.44 -41.20%
on 09/04/18
-12.87 (-30.26%)
since 08/10/18
52-Week
27.27 +8.76%
on 04/11/18
50.44 -41.20%
on 09/04/18
-1.89 (-5.99%)
since 11/10/17

Most Recent Stories

More News
Myriad to Present New Data from Its Industry-Leading Portfolio of Genetic Tests for Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 studies will be featured at the San Antonio Breast Cancer Symposium (SABCS) being held Dec. 4-8,...

MYGN : 29.66 (-3.86%)
Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag

Myriad Genetics (MYGN) witnesses strong performance by GeneSight, EndoPredict, and Prolaris tests in Q1.

MMSI : 57.94 (-2.06%)
SYK : 170.01 (-0.72%)
MYGN : 29.66 (-3.86%)
ISRG : 504.00 (-5.36%)
Myriad Genetics (MYGN) Beats Q1 Earnings Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 43.33% and -0.80%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

MYGN : 29.66 (-3.86%)
Myriad: Fiscal 1Q Earnings Snapshot

SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported a fiscal first-quarter loss of $700,000, after reporting a profit in the same period a year earlier.

MYGN : 29.66 (-3.86%)
Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results

-- First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent

MYGN : 29.66 (-3.86%)
Myriad Presents Two New Studies at the Western Section of the American Urological Association

New Data Demonstrate the Clinical Performance of the Prolaris and myRisk Hereditary Cancer Genetic Tests in Men with Prostate Cancer

MYGN : 29.66 (-3.86%)
SmarTrend Watching for Potential Rebound in Shares of Myriad Genetics After 12.11% Loss

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $37.44 to a high of $44.65. Yesterday, the shares fell 12.1%, which took the trading range below the 3-day low of...

MYGN : 29.66 (-3.86%)
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?

Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.

HSIC : 84.85 (-0.68%)
MYGN : 29.66 (-3.86%)
HAE : 105.26 (-5.69%)
QDEL : 63.01 (-4.62%)
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?

Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.

HOLX : 40.97 (-1.94%)
MYGN : 29.66 (-3.86%)
HAE : 105.26 (-5.69%)
QDEL : 63.01 (-4.62%)
Myriad Genetics to Present at the Stephens New York Investment Conference

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that R. Bryan Riggsbee, CFO, is scheduled to present at the Stephens New York Investor...

MYGN : 29.66 (-3.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MYGN with:

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 31.35
1st Resistance Point 30.50
Last Price 29.66
1st Support Level 29.22
2nd Support Level 28.79

See More

52-Week High 50.44
Fibonacci 61.8% 41.59
Fibonacci 50% 38.85
Fibonacci 38.2% 36.12
Last Price 29.66
52-Week Low 27.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar